Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.

Article Details

Citation

Copy to clipboard

Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM

Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.

Pediatr Transplant. 2008 Jun;12(4):456-63. doi: 10.1111/j.1399-3046.2007.00832.x.

PubMed ID

18466433 [ View in PubMed

]

Abstract

There are few prospective clinical trials of mTOR inhibitors (or proliferation signal inhibitors) combined with CNI inhibitors in de novo pediatric renal transplantation. Results reported here are from a multicenter, open-label study in de novo pediatric renal transplant patients (

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Everolimus	Serine/threonine-protein kinase mTOR	Protein	Humans	Yes	Inhibitor	Details